These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17603266)

  • 1. [Pharmacokinetic and molecular biological approaches to achieve the safety and effective management of drug therapies].
    Iwamoto T
    Yakugaku Zasshi; 2007 Jul; 127(7):1077-80. PubMed ID: 17603266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of pharmacists with expertise in infectious diseases to appropriate individualized vancomycin dosing.
    Nakashima T; Koido K; Baba H; Otsuka R; Okinaka K; Sano T; Nishigaki R; Hashimoto H; Otsuka T; Esaki M; Terakado H
    Pharmazie; 2018 Jul; 73(7):422-424. PubMed ID: 30001779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation of pharmacokinetic parameters with serum vancomycin concentration in elderly patients with malignancies].
    Sadoh S; Tsuji Y; Tsukamoto K
    Yakugaku Zasshi; 2010 Jan; 130(1):69-73. PubMed ID: 20046068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin.
    Hirai K; Ishii H; Shimoshikiryo T; Shimomura T; Tsuji D; Inoue K; Kadoiri T; Itoh K
    Ther Drug Monit; 2016 Dec; 38(6):706-710. PubMed ID: 27681114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients.
    Chuma M; Makishima M; Imai T; Tochikura N; Suzuki S; Kuwana T; Sawada N; Komatsu T; Sakaue T; Kikuchi N; Yoshida Y; Kinoshita K
    Ther Drug Monit; 2018 Feb; 40(1):109-114. PubMed ID: 29095798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases.
    Iwamoto T; Kagawa Y; Naito Y; Kuzuhara S; Kojima M
    Pharmacotherapy; 2004 Apr; 24(4):508-14. PubMed ID: 15098806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of systemic inflammatory response syndrome on the pharmacokinetics of vancomycin].
    Irikuchi J; Imai T; Yoshida Y; Orii T
    Yakugaku Zasshi; 2015; 135(5):745-51. PubMed ID: 25948312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
    Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency.
    Yamazaki S; Nakamura H; Yamagata S; Miura G; Hattori N; Shinozaki K; Sadahiro T; Toyoda A; Nakasa H; Ariyoshi N; Oda S; Harigaya K; Kitada M
    Int J Clin Pharmacol Ther; 2009 Nov; 47(11):701-6. PubMed ID: 19840535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of pharmacists' intervention on the antibiotic therapy for the methicillin-resistant Staphylococcus aureus (MRSA) infectious diseases in the intensive care unit].
    Imaura M; Kohata Y; Kobayashi K; Takahashi H; Yokoyama H; Akase T; Yamada Y
    Yakugaku Zasshi; 2011 Apr; 131(4):563-70. PubMed ID: 21467796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of a decision tree model for the analysis of adverse drug reactions: Evaluation of a risk prediction model of vancomycin-associated nephrotoxicity constructed using a data mining procedure.
    Imai S; Yamada T; Kasashi K; Kobayashi M; Iseki K
    J Eval Clin Pract; 2017 Dec; 23(6):1240-1246. PubMed ID: 28544476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Optimization of antimicrobial therapy based on therapeutic drug monitoring].
    Morita K
    Yakugaku Zasshi; 2011; 131(10):1407-13. PubMed ID: 21963966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bayesian forecasting of plasma vancomycin concentration using time-dependent pharmacokinetics].
    Nakamura T; Wakaki N; Kimura Y; Goto N; Masada M
    Yakugaku Zasshi; 1996 Nov; 116(11):876-83. PubMed ID: 8981831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nephrotoxicity of Vancomycin.
    Filippone EJ; Kraft WK; Farber JL
    Clin Pharmacol Ther; 2017 Sep; 102(3):459-469. PubMed ID: 28474732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations.
    Lonsdale DO; Udy AA; Roberts JA; Lipman J
    J Neurosurg; 2013 Feb; 118(2):297-301. PubMed ID: 23121433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.
    Han HK; An H; Shin KH; Shin D; Lee SH; Kim JH; Cho SH; Kang HR; Jang IJ; Yu KS; Lim KS
    Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of cerebral fluid drainage on the pharmacokinetics of vancomycin in neurosurgical patients.
    Ichie T; Urano K; Suzuki D; Okada T; Kobayashi N; Hayashi H; Sugiura Y; Yamamura K; Sugiyama T
    Pharmazie; 2015 Jun; 70(6):404-9. PubMed ID: 26189303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An extremely high bioavailability of orally administered vancomycin in a patient with severe colitis and renal insufficiency.
    Yamazaki S; Suzuki T; Suzuki T; Takatsuka H; Ishikawa M; Hattori N; Fujishiro T; Miyauchi H; Oami T; Ariyoshi N; Oda S; Matsubara H; Ishii I
    J Infect Chemother; 2017 Dec; 23(12):848-851. PubMed ID: 28923303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
    Rybak M; Lomaestro B; Rotschafer JC; Moellering R; Craig W; Billeter M; Dalovisio JR; Levine DP
    Am J Health Syst Pharm; 2009 Jan; 66(1):82-98. PubMed ID: 19106348
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin.
    Masuda N; Maiguma T; Komoto A; Haruki Y; Sugiyama T; Kondo S; Teshima D
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.